<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04727307</url>
  </required_header>
  <id_info>
    <org_study_id>RECHMPL20_0094 (UF 8008)</org_study_id>
    <nct_id>NCT04727307</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Atezo, Adjuvant Atezo + Beva Combined With RF Ablation of Small HCC: a Multicenter Randomized Phase II Trial</brief_title>
  <acronym>AB-LATE02</acronym>
  <official_title>Neoadjuvant Atezolizumab and Adjuvant Atezolizumab + Bevacizumab in Combination With Percutaneous Radiofrequency Ablation of Small HCC: a Multicenter Randomized Phase II Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Following the results of study IMbrave150, the combination Atezolizumab + Bevacizumab is a&#xD;
      promising treatment option for patients with HCC.&#xD;
&#xD;
      In addition, the high intrahepatic distant recurrence rate and accumulating evidence for a&#xD;
      metastatic mechanism encourages exploring adjuvant/neoadjuvant strategies targeting tumor&#xD;
      growth and metastatic escape in the context of percutaneous thermal ablation for small HCC.&#xD;
&#xD;
      Local ablation of HCC is therefore an &quot;ideal&quot; setting for testing atezolizumab + bevacizumab&#xD;
      in combination with ablation, with the aim of reducing the risk of recurrence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Liver cancer is the sixth most common cancer and the third leading cause of death from cancer&#xD;
      worldwide (source: Globocan 2018). Hepatocellular carcinoma (HCC) represents 80-90% of liver&#xD;
      cancers. Percutaneous thermal ablation (PTA) is a validated treatment option for very early&#xD;
      and early stage HCC, together with surgical resection and liver transplantation (EASL&#xD;
      Clinical Practice Guidelines: Management of hepatocellular carcinoma, J Hepatol 2018). Due to&#xD;
      its excellent tolerance, particularly in patients with portal hypertension or bearing&#xD;
      comorbidities, it now represents in France nearly 70% of the first-line curative treatment of&#xD;
      &quot;in Milan&quot; tumours. The risk of local tumor progression (LTP) is ≈10-20% in PTA series&#xD;
      (Nault, J Hepatol 2018; N'Kontchou et al., Hepatology (Baltimore, Md) 2009). In addition, the&#xD;
      long-term results of PTA are influenced by the high rate (up to 60-80% at 5 years) of&#xD;
      intrahepatic distant recurrence (IDR) (Nault et al., J Hepatol 2018), as observed also after&#xD;
      HCC surgical resection (EASL Clinical Practice Guidelines: Management of hepatocellular&#xD;
      carcinoma, J Hepatol 2018; Imamura et al., J Hepatol 2003). It is unknown whether early IDR&#xD;
      (2-3 years after PTA of &lt;3 cm HCC) is due to metastatic spread or de novo carcinogenesis.&#xD;
&#xD;
      Strong scientific rationale and emerging clinical data suggest that the combined vascular&#xD;
      endothelial growth factor (VEGF) / Programmed death-ligand 1 (PD-L1) blockade may be&#xD;
      clinically beneficial in a number of tumor types, including HCC. Therefore, local ablation in&#xD;
      HCC is an &quot; ideal &quot; context to test Atezolizumab + Bevacizumab in combination with ablation.&#xD;
      The investigators hypothesized that the combo of Atezolizumab + Bevacizumab and&#xD;
      radiofrequency ablation could improve recurrence-free survival (RFS) at 2 years.&#xD;
&#xD;
      The aim of this randomized multicentre phase II trial is to compare RFS at 2 years in the&#xD;
      experimental arm (Atezolizumab + Bevacizumab + RF ablation) versus the control arm (RF&#xD;
      ablation) according to HCC modified response evaluation criteria in solid tumours (mRECIST).&#xD;
      Thus the proposed use here of Atezolizumab as first neoadjuvant, then in combination with&#xD;
      Bevacizumab as adjuvants, should theoretically, and hopefully, limit the radiofrequency&#xD;
      ablation (RFA) pro-tumor effects. The RFS current rate value of 45% corresponding to the&#xD;
      standard procedure of RFA alone (i.e. in the Active Comparator arm) should be increasing to&#xD;
      at least 65% because of the addition of the biotherapy (i.e. in the Experimental arm). The&#xD;
      total duration of the project is scheduled for 2 years, plus a 3-year follow-up. The&#xD;
      patients' recruitment timeframe is set at 18 months. 202 patients are to be included, 101 per&#xD;
      arm.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 26, 2021</start_date>
  <completion_date type="Anticipated">July 2027</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Recurrence-free survival</measure>
    <time_frame>2 years after randomization</time_frame>
    <description>The primary outcome is to compare recurrence-free survival in patients treated by radiofrequency ablation versus neoadjuvant atezolizumab followed by radiofrequency ablation followed by adjuvant atezolizumab and bevacizumab.Recurrence is evaluated by the local investigator.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">202</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>Neoadjuvant Atezolizumab before radiofrequency ablation then adjuvant Atezolizumab + Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant atezolizumab and adjuvant atezolizumab + bevacizumab in combination with percutaneous radiofrequency ablation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Percutaneous radiofrequency ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Percutaneous radiofrequency ablation, standard treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab (neoadjuvant)</intervention_name>
    <description>Atezolizumab 1200mg will be delivered as an IV infusion on Day 1 of each cycle (every 3 weeks) in neoadjuvant, for 2 cycles. The initial dose will be delivered over 60 (± 15) minutes and if tolerated subsequent infusions may be given over 30 (± 10) minutes.</description>
    <arm_group_label>Neoadjuvant Atezolizumab before radiofrequency ablation then adjuvant Atezolizumab + Bevacizumab</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous Radiofrequency</intervention_name>
    <description>Any RFA system (uni/multi-needle, monopolar or multi-bi-polar) is allowed. Microwave ablation or irreversible electroporation is not allowed.</description>
    <arm_group_label>Neoadjuvant Atezolizumab before radiofrequency ablation then adjuvant Atezolizumab + Bevacizumab</arm_group_label>
    <arm_group_label>Percutaneous radiofrequency ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab (adjuvant)</intervention_name>
    <description>Bevacizumab 15 mg/kg will be delivered as an IV infusion on Day 1 of each 3 week cycle in adjuvant, for 15 cycles maximum. The initial dose will be delivered over 90 minutes (±15 minutes) and if tolerated subsequent infusions may be given over 60 (± 10) minutes then over 30 (± 10) minutes.</description>
    <arm_group_label>Neoadjuvant Atezolizumab before radiofrequency ablation then adjuvant Atezolizumab + Bevacizumab</arm_group_label>
    <other_name>Avastin 400 mg in 16 ml Injection</other_name>
    <other_name>Avastin 100 mg in 4 ml Injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atezolizumab (adjuvant)</intervention_name>
    <description>Atezolizumab 1200 mg will be delivered as an IV infusion on Day 1 of each cycle (every 3 weeks) in adjuvant, for 15 cycles maximum. The dose will be delivered over 30 (± 10) minutes.</description>
    <arm_group_label>Neoadjuvant Atezolizumab before radiofrequency ablation then adjuvant Atezolizumab + Bevacizumab</arm_group_label>
    <other_name>Tecentriq</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male or female patients ≥ 18 years of age&#xD;
&#xD;
          2. Diagnostic of HCC based on histology&#xD;
&#xD;
          3. Patients with HCC eligible for ablation as assessed by multidisciplinary board:&#xD;
&#xD;
               -  All HCC nodules &lt;3cm&#xD;
&#xD;
               -  1-3 nodules of HCC&#xD;
&#xD;
          4. At least one uni-dimensional measurable lesion by magnetic resonance imaging (MRI)&#xD;
             according to modified RECIST criteria&#xD;
&#xD;
          5. Liver function status Child-Pugh Class A&#xD;
&#xD;
          6. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 1&#xD;
&#xD;
          7. Adequate bone marrow, liver and renal function as assessed by the following laboratory&#xD;
             tests:&#xD;
&#xD;
               -  Hemoglobin &gt; 8.5 g/dL&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1500/mm3&#xD;
&#xD;
               -  Platelet count ≥ 50,000/ mm3&#xD;
&#xD;
               -  Total bilirubin ≤ 2 mg/dL (ou ≤ 34 µmol/ L).&#xD;
&#xD;
               -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 5 x upper&#xD;
                  limit of normal (ULN)&#xD;
&#xD;
               -  Serum creatinine ≤ 1.5 x ULN&#xD;
&#xD;
               -  Lipase ≤ 2 x ULN&#xD;
&#xD;
               -  Prothrombin time &gt; 50%&#xD;
&#xD;
               -  Glomerular Filtration Rate (GFR) ≥ 35 mL/min/1.73 m2&#xD;
&#xD;
          8. Life expectancy ≥ 3 months&#xD;
&#xD;
          9. Women of childbearing potential and men must agree to use adequate contraception&#xD;
&#xD;
         10. Patients affiliated to a Social Security System&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with contraindications to ablation or atezolizumab or bevacizumab&#xD;
&#xD;
          2. Patients with contraindication to contrast medium intravenous injection either&#xD;
             gadolinium or iodinate&#xD;
&#xD;
          3. Patients with contraindication to MRI&#xD;
&#xD;
          4. Prior liver transplantation&#xD;
&#xD;
          5. Child-Pugh B or C&#xD;
&#xD;
          6. Patients with mixed histology (HCC and cholangiocarcinoma, namely&#xD;
             hepatocholangiocarcinoma)&#xD;
&#xD;
          7. Current or recent (≤ 10 days prior to initiation of study treatment) use of full-dose&#xD;
             oral or parenteral anticoagulants or thrombolytic agents for therapeutic (as opposed&#xD;
             to prophylactic) purpose. Prophylactic anticoagulation for the patency of venous&#xD;
             access devices is allowed provided the activity of the agent results in an INR &lt; 1.5 x&#xD;
             ULN and aPTT is within normal limits within 14 days prior to initiation of study&#xD;
             treatment. For prophylactic use of anticoagulants or thrombolytic therapies, the&#xD;
             approved dose as described by local label may be used.&#xD;
&#xD;
          8. Current or recent (≤10 days prior to initiation of study treatment) use of aspirin (&gt;&#xD;
             325 mg/day) or treatment with clopidogrel, dipyramidole, ticlopidine, or cilostazol.&#xD;
&#xD;
          9. Active or history of autoimmune disease or immune deficiency, including, but not&#xD;
             limited to, myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus&#xD;
             erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid&#xD;
             antibody syndrome, Wegener granulomatosis, Sjögren syndrome, Guillain-Barré syndrome,&#xD;
             or multiple sclerosis, with the following exceptions:&#xD;
&#xD;
               1. Patients with a history of autoimmune-related hypothyroidism who are on&#xD;
                  thyroid-replacement hormone are eligible for the study.&#xD;
&#xD;
               2. Patients with controlled Type 1 diabetes mellitus who are on an insulin regimen&#xD;
                  are eligible for the study.&#xD;
&#xD;
               3. Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with&#xD;
                  dermatologic manifestations only (e.g., patients with psoriatic arthritis are&#xD;
                  excluded) are eligible for the study provided all of following conditions are&#xD;
                  met:&#xD;
&#xD;
                    -  Rash must cover &lt; 10% of body surface area.&#xD;
&#xD;
                    -  Disease is well controlled at baseline and requires only low-potency topical&#xD;
                       corticosteroids.&#xD;
&#xD;
                    -  No occurrence of acute exacerbations of the underlying condition requiring&#xD;
                       psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic&#xD;
                       agents, oral calcineurin inhibitors, or high-potency or oral&#xD;
                       corticosteroids.&#xD;
&#xD;
         10. Treatment with systemic immunosuppressive medication (including, but not limited to,&#xD;
             corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide, and&#xD;
             anti-TNF-α agents) within 2 weeks prior to initiation of study treatment, or&#xD;
             anticipation of need forsystemic immunosuppressive medication during study treatment,&#xD;
             with the following exceptions:&#xD;
&#xD;
               -  Patients who received acute, low-dose systemic immunosuppressant medication or a&#xD;
                  onetime pulse dose of systemic immunosuppressant medication (e.g., 48 hours of&#xD;
                  corticosteroids for a contrast allergy) are eligible for the study after Medical&#xD;
                  Monitor confirmation has been obtained.&#xD;
&#xD;
               -  Patients who received mineralocorticoids (e.g., fludrocortisone), corticosteroids&#xD;
                  for chronic obstructive pulmonary disease (COPD) or asthma, or low-dose&#xD;
                  corticosteroids for orthostatic hypotension or adrenal insufficiency are eligible&#xD;
                  for the study.&#xD;
&#xD;
         11. Portal vein invasion, whatever its extent, shown on baseline imaging&#xD;
&#xD;
         12. Prior chemo-embolization or radio-embolization.&#xD;
&#xD;
         13. Patients with extra-hepatic metastases, either previously-treated or not. One lung&#xD;
             nodule (&lt;5mm) is allowed. Calcified lung micronodules as well as typical&#xD;
             intra-pulmonary lymph nodes are allowed. Hepatic hilum lymph node &lt; 10mm (short axis)&#xD;
             is allowed.&#xD;
&#xD;
         14. Prior surgery of HCC with micro- or macro-vascular invasion demonstrated at pathology.&#xD;
&#xD;
         15. Prior systemic treatment for HCC, in particular agents targeting T-cell costimulation&#xD;
             or checkpoint pathways (including those targeting PD-1, PD-L1 or PD-L2, cluster of&#xD;
             differentiation 137 (CD137), or cytotoxic T-lymphocyte antigen (CTLA-4)).&#xD;
&#xD;
         16. Patients with uncontrolled HBV infection and viral load above 500 IU/mL.&#xD;
&#xD;
         17. Untreated or incompletely treated esophageal and/or gastric varices with bleeding or&#xD;
             high risk for bleeding. Patients must undergo an esophagogastroduodenoscopy (EGD), and&#xD;
             all size of varices (small to large) must be assessed and treated per local standard&#xD;
             of care prior to enrollment. Patients who have undergone an EGD within 6 months of&#xD;
             prior to initiation of study treatment do not need to repeat the procedure&#xD;
&#xD;
         18. Past or concurrent history of neoplasm other than HCC, except for in-situ carcinoma of&#xD;
             the cervix uteri and/or non-melanoma skin cancer and superficial bladder tumors. Any&#xD;
             cancer curatively treated &gt; 3 years prior to study entry is permitted&#xD;
&#xD;
         19. Known history or symptomatic meningeal tumors&#xD;
&#xD;
         20. Grade 3 (severe) hypertension ≥160 and/or ≥100 mmHG (systolic and diastolic, according&#xD;
             to NCI-CTCAE v5.0)&#xD;
&#xD;
         21. Patients with phaeochromocytoma&#xD;
&#xD;
         22. Ongoing infection : Hepatitis B is allowed if no active replication is present (HBV&#xD;
             replication below 500 IU/mL) or Hepatitis C is allowed if no antiviral treatment is&#xD;
             required&#xD;
&#xD;
         23. Clinically significant bleeding NCI-CTCAE version 5.0 ≥ Grade 3 within 30 days before&#xD;
             enrolment (transfusion indicated)&#xD;
&#xD;
         24. Arterial or venous thrombotic or embolic events such as cerebrovascular accident, deep&#xD;
             vein thrombosis or pulmonary embolism within 6 months before enrolment&#xD;
&#xD;
         25. Any psychological, familial, sociological, geographical or illness or medical&#xD;
             condition that could jeopardize the safety of the patient and/or his compliance with&#xD;
             the study protocol and follow-up procedure&#xD;
&#xD;
         26. Known history of human immunodeficiency virus (HIV) infection&#xD;
&#xD;
         27. Seizure disorder requiring medication&#xD;
&#xD;
         28. Non-healing wound, ulcer or bone fracture&#xD;
&#xD;
         29. Breast feeding&#xD;
&#xD;
         30. Pregnancy&#xD;
&#xD;
         31. Legal incapacity (persons in custody or under guardianship)&#xD;
&#xD;
         32. Deprived of liberty Subject (by judicial or administrative decision)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boris GUIU, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>University Hospital, Montpellier</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wendy RENIER, PhD</last_name>
    <phone>+33 4 67 33 52 43</phone>
    <email>w-renier@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric NGUYEN-KHAC, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Thierry YZET, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU d'Angers</name>
      <address>
        <city>Angers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme LEBIGOT, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Frédéric OBERTI, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hôpital Jean Verdier</name>
      <address>
        <city>Bondy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pierre NAHON, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Olivier SEROR, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hôpital Beaujon</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maxime RONOT, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Mohamed BOUATTOUR, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Centre Georges François Leclerc</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>François GHIRINGHELLI, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Nathalie MEJEAN, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Romaric LOFFROY, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Sylvain MANFREDI, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU de Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas DECAENS, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Julien GHELFI, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Géraldine SERGENT, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Stéphane CATTAN, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Joseph</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Olivier MONNET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Xavier ADHOUTE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Boris GUIU, MD, PhD</last_name>
      <phone>+33 4 67 33 75 46</phone>
      <email>b-guiu@chu-montpellier.fr</email>
    </contact>
    <contact_backup>
      <last_name>Eric ASSENAT, MD, PhD</last_name>
      <phone>+33 4 67 33 01 37</phone>
      <email>e-assenat@chu-montpellier.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yann TOUCHEFFEU, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Jérémy MEYER, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU de Nice</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick CHEVALLIER, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Rodolphe ANTY, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU Nîmes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julien FRANDON, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Valérie PHOUTTHASSANG, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Hôpital Cochin</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anthony DOHAN, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Clémence HOLLANDE, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CH Perpignan</name>
      <address>
        <city>Perpignan</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Faiza KHEMISSA, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Geoffroy FAROUIL, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU de Poitiers</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Pierre TASU, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Claire BOYER, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vanessa BRUN, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Thomas UGUEN, MD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thierry DE BAERE, MD</last_name>
    </contact>
    <contact_backup>
      <last_name>Valérie BOIGE, MD</last_name>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 22, 2021</study_first_submitted>
  <study_first_submitted_qc>January 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atezolizumab</keyword>
  <keyword>Bevacizumab</keyword>
  <keyword>Percutaneous radiofrequency</keyword>
  <keyword>Ablation</keyword>
  <keyword>Liver disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

